Ocular Therapeutix Company Profile (NASDAQ:OCUL)

About Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix logoOcular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OCUL
  • CUSIP: N/A
  • Web: www.ocutx.com
Capitalization:
  • Market Cap: $195.07 million
  • Outstanding Shares: 29,028,000
Average Prices:
  • 50 Day Moving Avg: $9.41
  • 200 Day Moving Avg: $8.86
  • 52 Week Range: $4.04 - $11.91
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.31
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.9 million
  • Price / Sales: 102.67
  • Book Value: $2.21 per share
  • Price / Book: 3.04
Profitability:
  • EBIDTA: ($47,550,000.00)
  • Net Margins: -2,620.06%
  • Return on Equity: -80.26%
  • Return on Assets: -59.06%
Debt:
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 9.63%
  • Quick Ratio: 9.62%
Misc:
  • Average Volume: 1.45 million shs.
  • Beta: 1.73
  • Short Ratio: 5.55
 

Frequently Asked Questions for Ocular Therapeutix (NASDAQ:OCUL)

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) released its quarterly earnings data on Friday, May, 5th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.10. The company had revenue of $0.48 million for the quarter, compared to analysts' expectations of $0.51 million. Ocular Therapeutix had a negative net margin of 2,620.06% and a negative return on equity of 80.26%. During the same period last year, the company posted ($0.35) EPS. View Ocular Therapeutix's Earnings History.

Where is Ocular Therapeutix's stock going? Where will Ocular Therapeutix's stock price be in 2017?

6 brokerages have issued 1-year price objectives for Ocular Therapeutix's stock. Their forecasts range from $5.84 to $60.00. On average, they expect Ocular Therapeutix's share price to reach $23.31 in the next year. View Analyst Ratings for Ocular Therapeutix.

What are analysts saying about Ocular Therapeutix stock?

Here are some recent quotes from research analysts about Ocular Therapeutix stock:

  • 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/23/2017)
  • 2. Cantor Fitzgerald analysts commented, "We are initiating on Ocular Therapeutix with an Overweight rating and $35 Price target. We believe Ocular's portfolio of sustained release therapies have the potential to treat an array of ophthalmic conditions with significant unmet need. In focus, we view the upcoming FDA decision this year for lead developmental candidate DEXTENZA' in post-surgical ocular pain as a meaningful catalyst for the shares, and estimate that DEXTENZA could reach annual sales of $600 million at peak market penetration in 2023, with further growth to $900 million by 2030 for this indication alone in the U.S." (2/9/2017)

Who are some of Ocular Therapeutix's key competitors?

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the folowing people:

  • Amarpreet Sawhney Ph.D., Executive Chairman of the Board
  • Antony Charles Mattessich, President, Chief Executive Officer, Director
  • James Fortune, Interim Principal Financial Officer, Chief Operating Officer, Interim Princiapl Accounting Officer
  • George V. Migausky, Interim Chief Financial Officer
  • Eric P. Ankerud, Executive Vice President, Regulatory, Quality and Compliance
  • Andy Hurley, Chief Commercial Officer
  • Jonathan Talamo M.D., Chief Medical Officer
  • Jaswinder S. Chadha, Director
  • W. James O'Shea, Director
  • Jeffrey S. Heier M.D., Independent Director

Who owns Ocular Therapeutix stock?

Ocular Therapeutix's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Nottingham Advisors Inc. (0.50%), NEXT Financial Group Inc (0.14%) and Berson & Corrado Investment Advisors LLC (0.09%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney and James Fortune. View Institutional Ownership Trends for Ocular Therapeutix.

Who sold Ocular Therapeutix stock? Who is selling Ocular Therapeutix stock?

Ocular Therapeutix's stock was sold by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc and Berson & Corrado Investment Advisors LLC. View Insider Buying and Selling for Ocular Therapeutix.

How do I buy Ocular Therapeutix stock?

Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocular Therapeutix's stock price today?

One share of Ocular Therapeutix stock can currently be purchased for approximately $6.72.


MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ocular Therapeutix (NASDAQ:OCUL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $23.31 (246.83% upside)

Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
7/14/2017Morgan StanleyReiterated RatingEqual Weight$16.00 -> $8.00LowView Rating Details
7/12/2017Cantor FitzgeraldLower Price TargetOverweight -> Overweight$35.00 -> $21.00HighView Rating Details
3/13/2017Cowen and CompanyReiterated RatingOutperform$60.00MediumView Rating Details
11/15/2016Royal Bank Of CanadaReiterated RatingOutperform$30.00 -> $32.00N/AView Rating Details
8/11/2016JMP SecuritiesInitiated CoverageOutperform$21.00 -> $5.84N/AView Rating Details
8/5/2015NomuraInitiated CoverageBuy$46.00N/AView Rating Details
(Data available from 7/22/2015 forward)

Earnings

Earnings History for Ocular Therapeutix (NASDAQ:OCUL)
Earnings by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Earnings History by Quarter for Ocular Therapeutix (NASDAQ OCUL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2017Q1 2017($0.48)($0.58)$0.51 million$0.48 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.45)($0.52)$0.48 million$0.51 millionViewN/AView Earnings Details
11/9/2016Q316($0.50)($0.39)$0.47 million$0.48 millionViewListenView Earnings Details
8/9/2016Q216($0.49)($0.46)$0.55 million$0.44 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.44)$458.00 millionViewListenView Earnings Details
3/10/2016Q415($0.47)($0.43)$0.44 millionViewListenView Earnings Details
11/10/2015Q315($0.38)($0.47)$0.43 millionViewListenView Earnings Details
8/10/2015Q215($0.33)($0.45)$0.46 millionViewListenView Earnings Details
5/15/2015Q115($0.39)($0.35)$0.30 million$0.43 millionViewListenView Earnings Details
3/10/2015Q4($0.38)($0.37)$0.20 million$0.51 millionViewListenView Earnings Details
11/12/2014Q3 14($0.55)($0.48)$0.10 million$0.14 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)
Current Year EPS Consensus Estimate: $-2.22 EPS
Next Year EPS Consensus Estimate: $-2.03 EPS

Dividends

Dividend History for Ocular Therapeutix (NASDAQ:OCUL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ocular Therapeutix (NASDAQ:OCUL)
Insider Ownership Percentage: 26.10%
Institutional Ownership Percentage: 65.25%
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Amarpreet SawhneyInsiderBuy45,300$7.85$355,605.00View SEC Filing  
6/9/2016Amarpreet SawhneyCEOBuy10,000$6.70$67,000.00View SEC Filing  
11/17/2015Amarpreet SawhneyCEOBuy10,000$8.25$82,500.00View SEC Filing  
9/15/2015James FortuneCOOSell9,470$17.16$162,505.20View SEC Filing  
9/14/2015Amarpreet SawhneyCEOBuy15,000$16.50$247,500.00View SEC Filing  
6/15/2015Charles M WardenDirectorSell320,000$22.00$7,040,000.00View SEC Filing  
6/10/2015Charles M WardenDirectorSell427,000$22.00$9,394,000.00View SEC Filing  
6/10/2015Svlsf Iv, LlcMajor ShareholderSell1,119,000$22.00$24,618,000.00View SEC Filing  
7/30/2014Amarpreet SawhneyCEOBuy76,922$13.00$999,986.00View SEC Filing  
7/30/2014Svlsf Iv, LlcMajor ShareholderBuy715,380$13.00$9,299,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ocular Therapeutix (NASDAQ:OCUL)
Latest Headlines for Ocular Therapeutix (NASDAQ:OCUL)
Source:
DateHeadline
prnewswire.com logoInvestor Alert: Kaplan Fox Announces Investigation Of Ocular Therapeutix, Inc. - PR Newswire (press release)
www.prnewswire.com - July 21 at 5:17 AM
businesswire.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ocular Therapeutix, Inc. of a Class Action Lawsuit ... - Business Wire (press release)
www.businesswire.com - July 21 at 5:17 AM
finance.yahoo.com logoOCUL SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017
finance.yahoo.com - July 21 at 5:17 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 21 at 5:17 AM
americanbankingnews.com logo Analysts Expect Ocular Therapeutix, Inc. (NASDAQ:OCUL) to Announce -$0.64 Earnings Per Share
www.americanbankingnews.com - July 20 at 9:15 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) & Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - July 20 at 5:10 AM
finance.yahoo.com logoInvestor Alert: Kaplan Fox Announces Investigation Of Ocular Therapeutix, Inc.
finance.yahoo.com - July 20 at 5:10 AM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 20 at 5:10 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ocular Therapeutix, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2017
finance.yahoo.com - July 20 at 5:10 AM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocular Therapeutix, Inc. of a Class Action ... - Business Wire (press release)
www.businesswire.com - July 19 at 5:44 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocular Therapeutix, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2017
finance.yahoo.com - July 19 at 12:43 AM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 19 at 12:43 AM
finance.yahoo.com logoThe Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Ocular Therapeutix, Inc.
finance.yahoo.com - July 18 at 6:53 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 18 at 6:53 AM
americanbankingnews.com logoOcular Therapeutix, Inc. (NASDAQ:OCUL) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - July 17 at 11:05 AM
americanbankingnews.com logoFY2017 EPS Estimates for Ocular Therapeutix, Inc. Lifted by Cantor Fitzgerald (OCUL)
www.americanbankingnews.com - July 17 at 8:58 AM
businesswire.com logoEQUITY ALERT UPDATE: Rosen Law Firm Expands First Filed Securities Class Action against Ocular Therapeutix, Inc ... - Business Wire (press release)
www.businesswire.com - July 16 at 11:50 PM
businesswire.com logoThe Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws ... - Business Wire (press release)
www.businesswire.com - July 16 at 1:46 PM
businesswire.com logoRobbins Arroyo LLP: Ocular Therapeutix, Inc. (OCUL) Misled Shareholders According to a Recently Filed Class Action
www.businesswire.com - July 15 at 7:09 AM
finance.yahoo.com logoEQUITY ALERT UPDATE: Rosen Law Firm Expands First Filed Securities Class Action against Ocular Therapeutix, Inc. to Include Investors Who Purchased up to July 11, 2017
finance.yahoo.com - July 15 at 7:09 AM
finance.yahoo.com logoThe Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Ocular Therapeutix, Inc.
finance.yahoo.com - July 15 at 7:09 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular Therapeutix, Inc. of Class Action Lawsuit and Upcoming Deadline - OCUL
finance.yahoo.com - July 15 at 7:09 AM
americanbankingnews.com logoOcular Therapeutix, Inc. (OCUL) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 14 at 11:20 AM
americanbankingnews.com logoOcular Therapeutix, Inc. (OCUL) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - July 14 at 10:46 AM
prnewswire.com logoRM LAW Announces Class Action Lawsuit Against Ocular Therapeutix, Inc. - PR Newswire (press release)
www.prnewswire.com - July 14 at 7:05 AM
finance.yahoo.com logoOCUL INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocular Therapeutix, Inc.
finance.yahoo.com - July 14 at 7:05 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 14 at 7:05 AM
finance.yahoo.com logo​Ocular Therapeutix faces fraud allegations as FDA rejects eye drug
finance.yahoo.com - July 14 at 7:05 AM
finance.yahoo.com logoSafirstein Metcalf LLP Announces that A Class Action Has Been Filed Against Ocular Therapeutix, Inc. – OCUL
finance.yahoo.com - July 14 at 7:05 AM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 14 at 7:05 AM
rttnews.com logoOcular Therapeutix Gets CRL For DEXTENZA
www.rttnews.com - July 13 at 7:37 AM
News IconBRIEF-Ocular Therapeutix receives complete response letter from FDA for Dextenza NDA
www.businessinsider.com - July 13 at 7:37 AM
247wallst.com logoWhy Ocular Therapeutix Shares Are Getting Crushed
247wallst.com - July 13 at 7:37 AM
benzinga.com logoOcular Therapeutix Falls 30% After Major Setback In Dextenza
www.benzinga.com - July 13 at 7:36 AM
finance.yahoo.com logoThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Ocular Therapeutix, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - July 13 at 7:36 AM
finance.yahoo.com logoOCUL SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocular Therapeutix, Inc.
finance.yahoo.com - July 13 at 7:36 AM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 13 at 7:36 AM
finance.yahoo.com logoOCULAR THERAPEUTIX ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ocular Therapeutix, Inc. To Contact The Firm
finance.yahoo.com - July 13 at 7:36 AM
finance.yahoo.com logoIMPORTANT OCULAR THERAPEUTIX, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Ocular Therapeutix, Inc.
finance.yahoo.com - July 13 at 7:36 AM
finance.yahoo.com logoRM LAW Announces Class Action Lawsuit Against Ocular Therapeutix, Inc.
finance.yahoo.com - July 13 at 7:36 AM
finance.yahoo.com logoEQUITY ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Ocular Therapeutix, Inc.
finance.yahoo.com - July 13 at 7:36 AM
feeds.benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Ocular Therapeutix, Inc. and Certain Officers – OCUL
feeds.benzinga.com - July 12 at 7:46 PM
feeds.benzinga.com logoIMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - July 12 at 7:46 PM
americanbankingnews.com logoCantor Fitzgerald Trims Ocular Therapeutix, Inc. (NASDAQ:OCUL) Target Price to $21.00
www.americanbankingnews.com - July 12 at 12:44 PM
businesswire.com logoOCULAR THERAPEUTIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ... - Business Wire (press release)
www.businesswire.com - July 12 at 6:36 AM
reuters.com logoBRIEF-Ocular Therapeutix submits amendment to potentially extend review for Dextenza NDA - Reuters
www.reuters.com - July 12 at 6:36 AM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ocular ... - PR Newswire (press release)
www.prnewswire.com - July 12 at 6:36 AM
prnewswire.com logoBlock & Leviton Announces Class Action Lawsuit Against Ocular Therapeutix, Inc. (OCUL) And Encourages ... - PR Newswire (press release)
www.prnewswire.com - July 12 at 6:36 AM
marketwatch.com logoOcular Therapeutix shares plummet after FDA pushes back on eye-drug approval - MarketWatch
www.marketwatch.com - July 12 at 6:36 AM
fool.com logoHere's Why Ocular Therapeutix Inc Rose 25.6% Today - Motley Fool
www.fool.com - July 12 at 6:36 AM

Social

Chart

Ocular Therapeutix (OCUL) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by MarketBeat.com Staff